Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Terns Pharmaceuticals, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 103
- +24 vs. Q1 2023
- Shares held
- 57.7M
- +4.50M (+8.5%) vs. Q1 2023
- Total value
- $505.0M
- −$125.2M (−19.9%) vs. Q1 2023
- New holders
- 41
- 29 more added
- Sold out
- 17
- 22 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TERN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $75.4K |
| Q1 2026 | 317 | $6.56B |
| Q4 2025 | 248 | $4.95B |
| Q3 2025 | 141 | $665.7M |
| Q2 2025 | 130 | $310.0M |
| Q1 2025 | 138 | $229.4M |
| Q4 2024 | 157 | $477.2M |
| Q3 2024 | 156 | $663.1M |
| Q2 2024 | 126 | $446.7M |
| Q1 2024 | 112 | $414.8M |
| Q4 2023 | 103 | $412.7M |
| Q3 2023 | 93 | $310.4M |
| Q2 2023 | 103 | $505.0M |
| Q1 2023 | 79 | $630.2M |
| Q4 2022 | 65 | $506.2M |
| Q3 2022 | 45 | $178.1M |
| Q2 2022 | 42 | $36.5M |
| Q1 2022 | 44 | $50.0M |
| Q4 2021 | 37 | $116.7M |
| Q3 2021 | 34 | $174.3M |
| Q2 2021 | 36 | $203.8M |
| Q1 2021 | 42 | $393.7M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Terns Pharmaceuticals, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 6,657,992 | $58.3M | 6.99% | 00.0% | Unchanged |
| FMR LLC | 7,050,346 | $61.7M | 0.01% | −592,412−7.8% | Reduced |
| OrbiMed Advisors LLC | 7,619,135 | $66.7M | 1.30% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −1,350,000−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −629,098−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −128,186−100.0% | Sold out |
| Velan Capital Investment Management LP | 0 | $0 | 0.00% | −120,000−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −50,951−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −46,762−100.0% | Sold out |
| Mirabella Financial Services LLP | 0 | $0 | 0.00% | −33,334−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −20,356−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −18,356−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −16,276−100.0% | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −15,849−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −5,084−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −3,852−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |